Pamidronate Disodium has been administered concomitantly with commonly used anticancer agents eg. commonly used antitumor drugs (including aminogluthethimide, cisplatin, corticosteroids, cyclophosphamide, cytarabine, doxorubicin, etoposide, fluorouracil, megoestrol, melphalan, methotrexate, mitoxantrone, paclitaxel, tamoxifen, vinblastine and vincristine) without interactions occurring.
Pamidronate Disodium has been used in combination with calcitonin in patients with severe hypercalcaemia, resulting in a synergistic effect producing a more rapid fall in serum calcium.
Caution is indicated when Pamidronate Disodium is used with other potentially nephrotoxic drugs. In multiple myeloma patients, the risk of renal dysfunction may be increased when Pamidronate Disodium is used in combination with thalidomide.
Pamidronate Disodium should not be used concomitantly with other bisphosphonates.
Incompatibilities: Infusion bags made from polyvinylchloride and polyethylene (prefilled with 0.9% w/v sodium chloride solution or 5% w/v glucose solution), showed no incompatibility with Pamidronate Disodium.
To avoid potential incompatibilities, Pamidronate Disodium Injection is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution.
Pamidronate Disodium Injection must not be mixed with calcium-containing solution such as Ringer's solution.